Dec 23, 2021 via Shahriar Lahouti. Updated 30 June 2026. 

CONTENTS

• Preface
• Etiology
  • Background
  • Cuases 
• Risk factors
• Antidiabetic Medications
  • Mechanism of action
  • Non-insulin Anti-diabetic agents
  • Insulin
    • Insulin- Rapid reference
• Symptoms
• Complications
  • Why is hypoglycemia dangerous 
  • Hypoglycemia Unawareness
  • Other complications
• Definition & Diagnosis
  • Core Diagnostic Principles (Applicable to All Patients)
  • Diagnostic Approach in Diabetic Patients
• Diagnostic Workup
  • Core principles (applying to all patients)
  • Diagnostic workup in Diabetic Patients
  • Diagnostic Workup in Non-Diabetic Patients
    • Establish Whipple’s Triad
    • Exclude Artifactual Hypoglycemia (In Asymptomatic Patients)
    • Determine the Etiology
• Approach to treatment
  • Background 
  • Immediate Treatment
  • Diagnostic Threshold for Treatment
  • Subsequent Treatment & Monitoring (After Initial Correction)
  • Pharmacologic Considerations
  • Disposition and follow-up
• Avoiding Hypoglycemia in Adult Hospitalized Patients
  • Glycemic Goals
  • Treatment of Hyperglycemia in Hospitalized Patients
• RECAP
• References

Preface

Severe hypoglycemia is a medical emergency that, if prolonged, can lead to permanent brain damage. The 2026 American Diabetes Association (ADA) Standards of Care have introduced a unified, clinically actionable framework for its definition, risk stratification, and management, emphasizing a shift from a purely glucose-centric approach to a broader focus on patient safety and cardiovascular, kidney, and metabolic (CKM) health. This updated review synthesizes these latest guidelines with evidence from the Endocrine Society, the International Hypoglycemia Study Group, and critical care resources to provide a practical, evidence-based guide for the diagnosis and treatment of hypoglycemia in adult patients. Rapid identification and correction of (suspected) hypoglycemia remains the cornerstone of care, and this article aims to equip clinicians with the knowledge to achieve this safely and effectively.

Etiology

Background

• The causes of hypoglycemia can be broadly categorized by the patient’s underlying health status. In diabetic patients, most hypoglycemic episodes requiring emergency care are medication-related, with insulin and insulin secretagogues being the primary culprits. However, the 2026 ADA guidelines highlight the importance of a comprehensive review, as infection, worsening kidney function, and social determinants of health like food insecurity are also significant contributing factors. In non-diabetic patients, the differential diagnosis is broader, encompassing serious acute illnesses, endocrine deficiencies, and rare conditions like insulinomas or non-islet cell tumor hypoglycemia (NICTH). A key update from the ADA is the integration of a formal risk assessment (below) to identify high-risk patients, particularly those with impaired awareness of hypoglycemia or a recent history of severe events.

Causes 

1. Insulin
   • Accidental, suicidal, iatrogenic, factitious.
     • Risk varies by formulation (e.g., NPH and premixed have higher risk than basal analogs)
2. Drugs that increase insulin secretion
   • Sulfonylureas (Risk of hypoglycemia: Glyburide (glibenclamide) > glimepiride > glipizide) *.
   • Meglitinides (repaglinide, nateglinide). Lower risk than sulfonylureas due to rapid onset/offset, but still significant.
   • Pentamidine *.
3. Other medications (evidence for many of these drugs is questionable) +/- Renal failure *
   • Other diabetes medications not listed above (these usually don’t cause hypoglycemia on their own, but may synergize with other risk factors).
     • GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors are considered “low-risk” for hypoglycemia as monotherapy, but hypoglycemia risk increases substantially when combined with insulin or sulfonylureas. In clinical practice, it is often necessary to reduce the insulin or SU dose when adding one of these agents
     • Alpha-glucosidase Inhibitors, e.g., Acarbose, do not cause hypoglycemia alone. If hypoglycemia occurs (with insulin/SU), must treat with pure glucose (not sucrose) because acarbose blocks sucrose breakdown
   • Fluoroquinolones (esp. gatifloxacin) *
   • Neurologic: Phenytoin, Selegiline, Valproate, Tramadol.
   • Psychiatric: doxepin, haloperidol, fluoxetine, lithium, venlafaxine.
   • Cardiovascular:
     • Nonselective beta-blockers (propranolol, nadolol).
     • ACE inhibitors.
     • Disopyramide, quinidine.
   • NSAIDs (especially indomethacin).
   • Sulfonamides (e.g., Trimethoprim-Sulfamethoxazole)
   • Quinine.
   • Hydroxychloroquine, artemisinin antimalarials.
   • Salicylate intoxication.
   • Ethanol intoxication.
   • Renal failure (usually not by itself; note that renal dysfunction may cause accumulation of many medications. Moreover, the clearance of insulin is diminished) *.
4. Serious acute illness (can be ketotic) 2
   • Adrenal insufficiency.
   • Myxedema coma.
   • Hepatic failure.
   • Sepsis & related critical illness states (Cytokines may cause increased glucose utilization and reduced hepatic gluconeogenesis).
5. Hyperinsulinemic, nonketotic hypoglycemia (not acutely ill)
   1. Exogenous insulin administration
   2. Endogenous hyperinsulinism
      • Insulin secretagogues (listed individually above).
      • Postbariatric hypoglycemia:
        • Hypoglycemia is typically postprandial (rather than fasting hypoglycemia).
        • Multifactorial, may relate to dysregulation of GLP-1 levels, often treatable with dietary modification.
        • Often presents as a late complication after surgery (e.g., >1 year afterwards).
      • Insulinoma
   3. Non-islet cell tumor hypoglycemia (NICTH; paraneoplastic release of IGF-2) *: 
      • Tumors are generally large (>10 cm) by the time they cause hypoglycemia (unlike insulinomas). Tumor types:
        1. Mesenchymal tumors (~40%), e.g.:
           • Mesothelioma.
           • Leiomyosarcoma.
           • Gastrointestinal stromal tumors (GIST).
           • Fibrosarcomas.
           • Solitary fibrous tumor.
        2. Epithelial solid tumors (~40%), e.g.:
           • Hepatocellular carcinoma.
           • Gastric cancer.
           • Renal cell carcinomas.
6. Inadequate carbohydrate intake (usually ketotic)
   • Starvation, anorexia nervosa.
   • Exercise.
   • Pregnancy/lactation.
   • Alcohol bingeing (including alcoholic ketoacidosis) *
     • Alcohol depletes NAD⁺, inhibiting hepatic gluconeogenesis and glycogenolysis.
     • Acute alcohol intake in the context of depleted glycogen stores may cause hypoglycemia.

Risk factors

◾️Several risk factors have been associated with the development of hypoglycemia in patients treated with sulfonylureas or meglitinides *. The 2026 ADA Standards of Care provide a major update in the form of a structured Hypoglycemia Risk Assessment (table below). This new framework moves beyond simply listing risk factors to formally categorizing them as Major or Other risk factors, and crucially, it now explicitly includes Social, Cultural, and Economic determinants of health.

• Individuals are considered at high risk if they have one or more major risk factors (e.g., recent level 2 or 3 hypoglycemia, impaired awareness, kidney failure) or multiple other risk factors.
• This updated approach emphasizes that hypoglycemia prevention requires addressing not only clinical and biological factors (like insulin therapy or renal function) but also social challenges such as food insecurity, housing instability, and underinsurance, which are now recognized as major contributors to hypoglycemia risk.

Antidiabetic Medications

Mechanism of action

Non-insulin Antidiabetic Agents

• The choice of glucose-lowering therapy is a critical determinant of hypoglycemia risk. While metformin remains the foundational first-line therapy for type 2 diabetes, the 2026 ADA guidelines strongly advocate for a cardiovascular, kidney, and metabolic (CKM) framework, promoting the earlier use of agents with proven organ-protective benefits.
• The table below provides a comprehensive overview of non-insulin antidiabetic medications, organized by pharmacologic class. It highlights not only their mechanisms of action and glycemic efficacy but also their specific advantages, disadvantages, and crucial considerations regarding cardiovascular (CV) effects, weight changes, and the risk of hypoglycemia—key factors in individualizing therapy. Notably, while newer agents like GLP-1 receptor agonists and SGLT2 inhibitors have a low intrinsic risk of hypoglycemia, this risk significantly increases when combined with insulin or sulfonylureas, requiring careful dose adjustment.

Insulin 

Insulin remains the most potent glucose-lowering therapy and is essential for managing type 1 diabetes and advanced type 2 diabetes. However, its use is the single most important risk factor for hypoglycemia, as recognized in the 2026 ADA Standards of Care. The risk of hypoglycemia is not uniform across all insulin formulations; it is significantly influenced by the pharmacokinetic profile, which determines the onset, peak, and duration of action. A comprehensive understanding of these profiles is essential for safe and effective insulin prescribing, particularly for preventing and managing hypoglycemic events.

🚨Key Clinical Considerations for Hypoglycemia Risk

Insulin- Rapid reference table

The table below provides a rapid reference for the pharmacology, pharmacokinetics, and clinical use of different insulin types. The formulations are broadly categorized by their duration of action, from rapid-acting prandial insulins to ultra-long-acting basal analogues.

Symptoms

The symptoms of hypoglycemia are broadly classified into neurogenic (autonomic) and neuroglycopenic categories. However, these are nonspecific for the diagnosis of hypoglycemia. 

• Autonomic symptoms (sympathetic activation): Autonomic symptoms are generated from the autonomic nervous system and thus are catecholamine-driven
  • Diaphoresis.
  • Tremulousness, anxiety.
  • Tachycardia, palpitations, and increased blood pressure.
  • Hunger.
• Neuroglycopenic: These symptoms are generated because of the brain’s lack of glucose, causing decreased function. Brain dysfunction is usually the most obvious clinical finding.
  • Confusion.
  • Visual changes (blurred vision, diplopia).
  • Slurred speech, dizziness.
  • Seizures.
  • Eventually: lethargy, stupor, coma.

🚨The 2026 ADA guidelines emphasize that the glycemic threshold for these symptoms is not fixed; it shifts to higher glucose levels in patients with chronic hyperglycemia and to lower levels in those with recurrent hypoglycemia or impaired awareness.

• This variability underscores the importance of individualized glucose targets and the use of continuous glucose monitoring (CGM), which is now strongly recommended for high-risk patients to detect asymptomatic and nocturnal hypoglycemia.

Complications of Hypoglycemia

Why is hypoglycemia dangerous?

⚠️Prolonged severe hypoglycemia can cause permanent brain damage, similar to anoxic brain injury.

⚠️Hypoglycemia is most dangerous among intubated and sedated patients, because mental status changes won’t be immediately evident.

⚠️Generally, hypoglycemia is far more dangerous than hyperglycemia.

• The 2026 ADA guidelines stress that severe hypoglycemia is associated with increased mortality, cardiovascular events, and falls.
• The sympathoadrenal response to hypoglycemia can trigger arrhythmias and increase cardiac workload, while the inflammatory cascade it initiates contributes to endothelial dysfunction.

Hypoglycemia Unawareness & HAAF

• Definition:
  • Hypoglycemia-associated autonomic failure (HAAF) is a vicious cycle where recurrent hypoglycemia impairs the sympathoadrenal response, shifting the glycemic threshold for symptoms to lower levels. This leads to a loss of the early autonomic warning symptoms (hypoglycemia unawareness), dramatically increasing the risk of severe (Level 3) hypoglycemia.
• Mechanism 
  • Shifts glycemic thresholds for symptoms to lower plasma glucose concentrations, approaching levels that cause cognitive failure (Below left figure)
• Prevalence:
  • Type 1 diabetes: ~50% after 25 years of treatment
  • Type 2 diabetes: ~10%
  • Unclear if it develops in patients on oral agents alone
• Contributing factors: Recurrent hypoglycemia, physical exercise, and sleep impair defense mechanisms.
• Presumed pathophysiology:
  • Reduced autonomic response → attenuation of warning symptoms
  • Compensatory brain adaptation:
    • ↑ GLUT1 activity → preserves brain glucose uptake
    • Altered glucose sensing in ventromedial hypothalamus (VMH)
    • Mediated by elevated GABA levels
• Clinical consequence: Increased risk of severe hypoglycemia and impaired awareness, making hypoglycemia prevention the cornerstone of management.

Other complications

• Hypoglycemic events may induce inflammation by stimulating the release of C-reactive protein (CRP), IL-6, and vascular endothelial growth factor (VEGF).
• Hypoglycemia also increases platelet and neutrophil activation.
• Sympathoadrenal response during hypoglycemia increases adrenaline release and may lead to arrhythmias and increased cardiac workload.
• Endothelial dysfunction may also contribute to cardiovascular risk (Below right figure).

Definition & Diagnosis

The diagnostic approach to hypoglycemia differs fundamentally between patients with known diabetes and those without.

Core Diagnostic Principles (Applicable to All Patients)

◾️Whipple’s Triad: The Gold Standard

• Before diagnosing a hypoglycemic disorder, all patients must meet Whipple’s Triad. This is non-negotiable and is the foundation of diagnosis:
  1. Symptoms consistent with hypoglycemia (autonomic and/or neuroglycopenic)
  2. A low plasma glucose concentration documented by a laboratory assay (not a glucose meter or CGM) at the time of symptoms
  3. Resolution of symptoms after the plasma glucose level is raised

🚨Important Caveat: In a patient without diabetes, the presence of a low glucose value alone (e.g., 50 mg/dL) without symptoms is NOT diagnostic of a hypoglycemic disorder.

• Healthy individuals, particularly young women, can have glucose values in the 40-60 mg/dL range during prolonged fasting without symptoms. This is normal physiology. The symptoms are what give the low glucose clinical significance.

Diagnostic Approach in Diabetic Patients

◾️Definition

• In patients with diabetes, hypoglycemia is defined as all episodes of an abnormally low plasma glucose concentration (with or without symptoms) that expose the individual to harm. The ADA 2026 Standards of Care uses a unified three-tier classification:
  • Level 1 (<70 mg/dL [3.9 mmol/L]): Alert value. Triggers autonomic symptoms. Enables patient-initiated carbohydrate ingestion and self-correction.
    • Highest glucose threshold known to reduce sympathoadrenal responses to subsequent hypoglycemia.
  • Level 2 (<54 mg/dL [3.0 mmol/L]): Serious hypoglycemia. Threshold for neuroglycopenic symptoms and cognitive impairment. Requires immediate action.
    • Recommended endpoint for hypoglycemia reporting in clinical trials.
  • Level 3 (Requiring assistance): Severe hypoglycemia. Defined by an altered mental/physical status needing external assistance. Independent of glucose value.
    • Associated with increased mortality, cardiovascular events, and falls. Triggers glucagon/IV dextrose and mandates treatment plan reevaluation.
• Clinical value of updated definition:
  • Enables consistent communication among clinicians, patients, and caregivers
  • Guides individualized glycemic goals (balancing A1C with hypoglycemia risk)
  • Identifies impaired awareness (Level 2 without symptoms)
  • Supports appropriate technology use (CGM recommended for high-risk patients)
  • Mandates glucagon prescribing for all insulin-treated patients
• Bottom line: Hypoglycemia is the major barrier to safe glycemic control. The ADA 2026 definitions provide a standardized framework for timely recognition, appropriate treatment, and systematic prevention — improving patient safety and outcomes.

Diagnostic Workup

Core principles (applying to all patients)

• Review hypoglycemia history 
• Confirm with glucose measurement (BGM or CGM) whenever possible
• Identify contributing factors: medication errors, missed meals, exercise, alcohol, renal impairment, cognitive dysfunction, food insecurity.
  • Medication history:
    • The most common culprit is insulin or sulfonylurea misuse.
      • The patient’s medication history is critical, with the most common culprits being insulin and sulfonylureas, but newer agents like SGLT2 inhibitors should be reviewed for their potential to cause euglycemic DKA in the setting of illness.
    • Review new medications or dose changes.
    • Changes in renal or hepatic function may cause drug accumulation.
      • Adequacy of oral intake? 
      • Recent alcohol binge?
• Other features may suggest sepsis, chronic adrenal insufficiency, or hepatic failure.
• Assess response to treatment: Hypoglycemia is the most likely diagnosis if symptoms abate after glucose administration. However, if these symptoms persist, alternative diagnoses should be considered and investigated.

Diagnostic workup in Diabetic Patients

• History: 
  • Review history of hypoglycemia at every clinical encounter.
  • Identify symptoms, frequency, timing (nocturnal vs. daytime), severity, and any identified precipitants (missed meals, exercise, medication errors, alcohol).
  • Assess for impaired hypoglycemia awareness at least annually using validated tools (e.g., Clarke, Gold, or Pedersen-Bjergaard single question) 
• Glucose Confirmation:
  • Blood Glucose Monitoring (BGM): Fingerstick glucose is the front-line test. However, it may be inaccurate in patients with poor perfusion.
  • Continuous Glucose Monitoring (CGM): Recommended for individuals at high risk of hypoglycemia. CGM detects asymptomatic and nocturnal hypoglycemia and identifies glycemic patterns.
  • Laboratory Glucose: This is the gold standard. If there is any doubt about BGM or CGM accuracy (e.g., in poor perfusion, suspected artifactual hypoglycemia), send blood to the lab for confirmation. Treatment should not be delayed while awaiting lab results in a symptomatic patient.
• Risk Stratification
  • Assess for major and other risk factors (e.g., recent level 2/3 hypoglycemia, intensive insulin therapy, impaired awareness, CKD, cognitive impairment, food insecurity).
  • Individuals with ≥1 major risk factor or multiple other risk factors are considered high-risk.
• Treatment Plan Reevaluation
  • Any Level 2 or Level 3 event should prompt a reevaluation of the treatment plan, including de-intensifying or switching medications (e.g., reducing insulin, sulfonylurea, or meglitinide doses).

Diagnostic Approach in Non-Diabetic Patients

◾️Definition

• A hypoglycemic disorder in a person without diabetes is diagnosed only when Whipple’s Triad is fulfilled. This is more stringent because hypoglycemia is uncommon and often pathologic.

Step 1: Establish Whipple’s Triad

1. Measure Glucose During Symptoms:
   • Laboratory Measurement (Preferred): The patient should have a lab draw during a symptomatic episode. If symptoms are predictable, they can go to the lab and try to elicit symptoms (e.g., by fasting or eating a meal that typically provokes symptoms).
   • Home Glucose Monitoring: If lab testing is not feasible, provide a glucose meter and instruct the patient to check fingerstick glucose whenever symptoms occur. Record all values and symptoms.
     • Fingerstick Glucose < 65 mg/dL (3.6 mmol/L) with symptoms → Likely hypoglycemic disorder. Refer to endocrinology.
     • Fingerstick Glucose ≥ 65 mg/dL (3.6 mmol/L) with symptoms → Hypoglycemia is very unlikely. Evaluate for other causes (e.g., postprandial syndrome, cardiac arrhythmia, anxiety).
     • Fingerstick Glucose ≥80 mg/dL (4.4 mmol/L) → Hypoglycemia is excluded as the cause of symptoms.
2. Check for Resolution of Symptoms:
   • Document that symptoms resolve after the glucose level is raised (e.g., after carbohydrate ingestion or IV dextrose). This is the third criterion of Whipple’s Triad.

Step 2: Exclude Artifactual Hypoglycemia (In Asymptomatic Patients)

• If a low glucose is found incidentally on routine labs, the first step is to exclude artifactual hypoglycemia.
  • Causes: Prolonged sample processing (especially without fluoride), severe leukocytosis, erythrocytosis, or hemolysis can cause a falsely low glucose reading.
  • Action: Repeat the glucose measurement with proper sample collection (sodium fluoride tube, placed on ice, centrifuged promptly).

Step 3: Determine the Etiology

• Once Whipple’s Triad is confirmed, a detailed clinical history guides further investigation:
  • Complete blood count with differential (elevated neutrophil/lymphocyte ratio may indicate sepsis or acute stress).
  • Liver function tests.
  • Urinalysis: Urinary ketones ≧2+ have similar implications to an elevated level of beta-hydroxybutyrate
  • Beta-hydroxybutyrate:
    • Beta-hydroxybutyrate is a fundamental test to direct the evaluation of hypoglycemia.
    • Low levels (<2.7 mM) suggest a hyperinsulinemic, nonketotic state (above).
    • Elevated levels (>2.7 mM) exclude a hyperinsulinemic, nonketotic state (because insulin suppresses ketone production). Ketoacidosis would support one of the following etiologies:
      • Inadequate carbohydrate intake (see above) – most strongly suggested, especially if beta-hydroxybutyrate levels are highly elevated.
      • Serious acute illness (above) – may occur in combination with ketoacidosis.
  • Insulin level
    • Insulin level > 3 micro-units/ml (21 pM) in the context of hypoglycemia suggests pathologically excessive insulin levels.  This may reflect either endogenous insulin synthesis or exogenous insulin administration.
    • Unfortunately, some synthetic forms of insulin may not be detected by the assay (e.g., glargine).
  • C-peptide level
    • Measures only endogenous insulin production, allowing differentiation between endogenous over-production of insulin versus exogenous insulin administration.
    • C-peptide level >0.2 nM (0.6 ng/ml) in the context of hypoglycemia suggests pathologically elevated insulin secretion by the pancreas.
  • Cortisol level to exclude adrenal insufficiency
    • Generally, a stressed, hypoglycemic patient should have somewhat elevated levels of cortisol.  Low levels should alert to the possibility of adrenal insufficiency.
    • When in doubt, an ACTH stimulation test should be performed to clarify.
  • TSH.
  • Salicylate level (if salicylate intoxication is possible).
  • Other diagnostic considerations
    • Screening lab tests that should be sent should search for an etiology, such as infection. If the etiology is simply overmedication or underconsumption of nutrition, the workup can be very minimal.
    • A screening creatinine level is recommended because patients may not be symptomatic from renal insufficiency.

Approach to Treatment

Background

The treatment of hypoglycemia requires a nuanced, two-phase approach: immediate correction of the low glucose and subsequent prevention of recurrence.

A key clinical pearl, emphasized in critical care literature, is that following a dextrose bolus, blood glucose peaks rapidly and falls back to baseline within 30 minutes, necessitating frequent monitoring and titration to avoid rebound hypoglycemia.

• Following D50% administration, the blood glucose typically changes as
• • Blood glucose peaks at ~5 min, remains elevated for ~15 min, then returns to baseline after ~30 min. These changes are due to the volume of distribution of dextrose.
  • This underscores the need for frequent blood glucose monitoring (every 15-30 min) following D50% infusion, as blood glucose will inherently fall.
  • Treatments should be titrated to achieve a safe glucose level (e.g., 100-200 mg/dL).
  • ⚡️Pushing the glucose too high can be counterproductive, as this can stimulate endogenous insulin release, leading to rebound hypoglycemia.

Immediate Treatment

The immediate treatment of hypoglycemia is the same for diabetic and non-diabetic patients and depends on the patient’s mental status and IV access.

• For conscious patients, the “Rule of 15” (15g of fast-acting glucose, recheck in 15 minutes) is the standard.
• The 2026 ADA explicitly recommends ready-to-use glucagon formulations (intranasal, prefilled syringe) for unconscious patients without IV access, as they are easier to administer and preferred over formulations requiring reconstitution.

Diagnostic Threshold for Treatment

This table clarifies a key clinical distinction: the threshold for treating hypoglycemia differs.

• In diabetic patients, a glucose of <70 mg/dL is an “alert value” mandating action to prevent progression, even if asymptomatic.
• In non-diabetic patients, treatment is only indicated if the low glucose is symptomatic and Whipple’s Triad is confirmed.

Subsequent Treatment & Monitoring (After Initial Correction)

After initial correction, the focus shifts to preventing recurrence, which is a greater concern in diabetic patients due to the ongoing pharmacology of their medications (e.g., long-acting insulin or sulfonylureas).

• A major update is the specific recommendation for a continuous D10 infusion (e.g., 100 mL/hr) for diabetic patients who remain hypoglycemic or cannot take oral intake, titrated to a target of 100-180 mg/dL. 🚨This is preferred over D50 for infusion as it is iso-osmolar and less irritating to veins.

Pharmacologic Considerations

The choice of follow-up therapy differs significantly. In diabetic patients, the treatment plan must be reevaluated and potentially de-intensified, which is an official recommendation (Grade B) for any Level 2 or 3 event.

For sulfonylurea overdose, octreotide is the specific antidote in both diabetic and non-diabetic patients, as it suppresses the unregulated insulin secretion that causes recurrent hypoglycemia.

Disposition and follow-up

• If a patient’s hypoglycemia can be attributed to inadequate oral (PO) intake or an inadvertent increase in short-acting or intermediate-acting insulin, the patient is alert, tolerating PO, and clinically stable, and glucose is stable on multiple rechecks, the patient may be discharged.
• In hypoglycemic patients on longer-acting insulin, the situation is different as:
  • Glargine (Lantus): It has an onset of action of 1-2 hours. However, there is no peak of insulin levels (see above). This is equivalent to the basal rate of insulin released by the pancreas. Once patients are stabilized and meet the discharge criteria mentioned above, they can be discharged home.
  • Levemir: It has an onset of action of 1-2 hours, lasts 24 hours, and has a peak action at about 6-8 hours. These patients should be observed for 6-8 hours to make sure they don’t drop again. Once they have crossed that threshold, if they are maintaining glucose levels, able to tolerate oral intake, and follow up with their primary care doctor, they can be discharged home.
• Otherwise, the patient should be admitted to a monitored bed.
• Patients requiring more frequent fingerstick glucose checks on dextrose infusions may require a higher level of care, such as in an intermediate medical care unit or intensive care unit (ICU), depending on local institutional policies regarding the frequency of fingerstick monitoring.
• If sulfonylurea poisoning is suspected or confirmed, the patient is at risk for recurrent hypoglycemia and should be admitted for monitoring and consideration of ongoing octreotide therapy.

👉After you treat hypoglycemia, follow the patient’s glucose carefully. Hypoglycemia frequently recurs. For example, insulin or sulfonylurea overdoses will outlast the glucose you give to the patient.

Avoiding Hypoglycemia in Adult Hospitalized Patients

Glycemic Goals

The 2026 ADA has introduced a significant update to inpatient glycemic goals, distinguishing them by the patient’s level of care.

• For critically ill patients in the ICU, the recommended target remains 140–180 mg/dL, based on evidence that stricter targets increase mortality and severe hypoglycemia.
• For non-critically ill patients, the new goal is a broader range of 100–180 mg/dL, which provides greater flexibility and safety.

Crucially, the target is determined by the clinical setting (ICU vs. non-ICU), not by the patient’s diabetes status.

The initiation threshold for therapy in both settings is ≥180 mg/dL on two occasions.

Treatment of Hyperglycemia in Hospitalized Patients

In the hospital, insulin is the preferred treatment for persistent hyperglycemia. For critically ill patients, a continuous IV insulin infusion is the standard of care due to its rapid titratability and short half-life.

For non-critically ill patients, subcutaneous basal-bolus insulin regimens are preferred over sliding-scale insulin alone, which is now considered less effective and more dangerous. The starting dose is often 0.3–0.5 units/kg/day.

The 2026 guidelines and expert consensus (Endotext) emphasize that a glucose level below 100 mg/dL in a non-ICU patient should be a trigger to adjust therapy, as it predicts impending hypoglycemia.

🚨Patients with cirrhosis or acute hepatic failure tend to develop hypoglycemia, so monitor their glucose levels and avoid giving them insulin. Some patients with severe hepatic failure will require a continuous dextrose infusion to avoid hypoglycemia.

RECAP

Key Clinical Pearls for Hypoglycemia Management

1. Diagnosis & Definitions
   • Know the ADA 2026 Three-Tier System: Use the unified definitions: Level 1 (<70 mg/dL, alert value), Level 2 (<54 mg/dL, serious hypoglycemia requiring action), and Level 3 (severe event requiring assistance, irrespective of glucose).
   • Whipple’s Triad is Mandatory for Non-Diabetics: Diagnosis requires symptoms + a low laboratory glucose + resolution after correction. A low glucose without symptoms is not a diagnosis.
   • In Diabetics, <70 mg/dL is an “Alert Value”: This mandates action (treatment or avoidance of critical tasks) even if asymptomatic, as it predicts future severe events.
2. Treatment: Immediate & Subsequent
   • The “Rule of 15” is Universal: For conscious patients, give 15-20g of fast-acting glucose and recheck in 15 minutes. Avoid foods high in fat or protein for initial treatment.
   • Ready-to-Use Glucagon is Preferred: For unconscious patients without IV access, use intranasal or prefilled syringe glucagon preparations.
   • D10 Infusion for Persistent Hypoglycemia: If a diabetic patient remains hypoglycemic or cannot eat after a D50 bolus, start a continuous D10 infusion (e.g., 100 mL/hr) titrated to a target of 100-180 mg/dL. D10 is iso-osmolar and less irritating to veins than D50.
3. Special Populations & Medications
   • Octreotide for Sulfonylurea Overdose: This applies to both diabetic and non-diabetic patients. Give a 100 mcg IV load, then 50 mcg SQ q6h to suppress unregulated insulin secretion.
   • Higher Hypoglycemia Risk with Combination Therapy: GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors have low risk as monotherapy, but hypoglycemia risk increases substantially when combined with insulin or sulfonylureas. Reduce the insulin/SU dose when adding these agents.
   • Insulin Formulation Matters: Risk of hypoglycemia is highest with premixed insulins, followed by NPH, and is lowest with long-acting (glargine, detemir) and ultra-long-acting (glargine U-300, degludec) analogues.
   • Use CGM for High-Risk Patients: Continuous glucose monitoring is strongly recommended to detect asymptomatic and nocturnal hypoglycemia
4. Inpatient Glycemic Management
   • ICU vs. Non-ICU Goals (ADA 2026): The target is determined by the level of care, not diabetes status.
     • ICU: Aim for 140–180 mg/dL.
     • Non-ICU: Aim for the new, broader range of 100–180 mg/dL.
   • Insulin is the Preferred Hospital Treatment: Use continuous IV insulin infusion in the ICU (Regular human insulin is the only one approved for IV use) and subcutaneous basal-bolus regimens on the wards. Avoid sliding-scale insulin alone.
5. The Ultimate Goals Differ
   • In Diabetics: Treat the acute episode, prevent recurrence, and adjust the chronic regimen to reduce future risk (e.g., de-intensify therapy, switch from glyburide to a safer agent).
   • In Non-Diabetics: Treat the acute episode, identify the underlying cause, and treat it definitively (e.g., stop the offending drug, resect an insulinoma, treat adrenal insufficiency).

References